Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 20/20 | 0.83 |
| ▸ | CA1 | P00915 | 20/20 | 0.83 |
| ▸ | CA2 | P00918 | 20/20 | 0.83 |
| ▸ | CA5A | P35218 | 20/20 | 0.83 |
| ▸ | CA9 | Q16790 | 20/20 | 0.83 |
| ▸ | CA5B | Q9Y2D0 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31213329 | 1.00 | CA12 (0.83) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL20876180 | 1.00 | CA12 (0.83) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL22405737 | 1.00 | CA12 (0.83) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL31388226 | 0.94 | CA12 (0.73) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL29635266 | 0.94 | CA12 (0.73) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL29635247 | 0.94 | CA12 (0.73) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL20897298 | 0.92 | CA12 (0.88) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL1177291 | 0.91 | CA12 (1.00) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL20897307 | 0.91 | CA12 (0.86) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL30123365 | 0.91 | CA12 (1.00) | CA12CA1CA2CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137669-A1 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2026-05-21 | — | — | US | claimed |
| US-20250115565-A1 | SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND PROCESS OF PREPARATION THEREOF | INNOVATIVE MOLECULES GMBH (DE) | 2025-04-10 | — | — | US | claimed |
| EP-4466255-A1 | SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND PROCESS OF PREPARATION THEREOF | Innovative Molecules GmbH (DE) | 2024-11-27 | — | — | EP | claimed |
| US-20240316021-A1 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2024-09-26 | — | — | US | claimed |
| WO-2023135303-A1 | SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND PROCESS OF PREPARATION THEREOF | INNOVATIVE MOLECULES GMBH (DE) | 2023-07-20 | — | — | WO | claimed |
| US-11278534-B2 | Enantiomers of substituted thiazoles as antiviral compounds | Innovative Molecules GmbG (DE) | 2022-03-22 | — | — | US | claimed |
| US-20200289486-A1 | Enantiomers Of Substituted Thiazoles As Antiviral Compounds | INNOVATIVE MOLECULES GMBH (DE) | 2020-09-17 | — | — | US | claimed |
| EP-3692039-A1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | Innovative Molecules GmbH (DE) | 2020-08-12 | — | — | EP | claimed |
| WO-2019068817-A1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2019-04-11 | — | — | WO | claimed |
| EP-4747240-A1 | MICRONIZED CRYSTALLINE HYDROCHLORIDE SALTS OF ANTIVIRAL HELICASE-PRIMASE INHIBITOR COMPOUNDS | Innovative Molecules GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137669-A1 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2026-05-21 | — | — | US | disclosed |
| US-12527778-B2 | Enantiomers of a series of antiviral compounds | INNOVATIVE MOLECULES GMBH (DE) | 2026-01-20 | — | — | US | disclosed |
| EP-4580601-A1 | PHARMACEUTICAL COMPOSITIONS FOR HERPES VIRUS | Assembly Biosciences, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| US-12295945-B2 | Enantiomers of substituted thiazoles as antiviral compounds | INNOVATIVE MOLECULES GMBH (DE) | 2025-05-13 | — | — | US | disclosed |
| US-20210401810-A1 | Helicase Primase Inhibitors For Treating Cancer In A Combination Therapy With Oncolytic Viruses | INNOVATIVE MOLECULES GMBH (DE) | 2021-12-30 | — | — | US | disclosed |
| US-20200289486-A1 | Enantiomers Of Substituted Thiazoles As Antiviral Compounds | INNOVATIVE MOLECULES GMBH (DE) | 2020-09-17 | — | — | US | disclosed |
| EP-3692039-A1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | Innovative Molecules GmbH (DE) | 2020-08-12 | — | — | EP | disclosed |
| WO-2020109389-A1 | HELICASE PRIMASE INHIBITORS FOR TREATING CANCER IN A COMBINATION THERAPY WITH ONCOLYTIC VIRUSES | INNOVATIVE MOLECULES GMBH (DE) | 2020-06-04 | — | — | WO | disclosed |
| WO-2019068817-A1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019068817-A1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12295945-B2 | Enantiomers of substituted thiazoles as antiviral compounds | EIF2AK2, MAVS, ZC3HAV1 | CA12 4867/4885CA1 4865/4885CA2 4604/4885 |
| US-20240316021-A1 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, SARS1 | CA12 4748/4885CA1 4827/4885CA2 4611/4885 |
| US-11278534-B2 | Enantiomers of substituted thiazoles as antiviral compounds | EIF2AK2, MAVS, ZC3HAV1 | CA12 4855/4885CA1 4850/4885CA2 4269/4885 |
| US-20210401810-A1 | Helicase Primase Inhibitors For Treating Cancer In A Combination Therapy With Oncolytic Viruses | DNA2, DDX24, DDX41 | CA12 3243/4885CA1 3457/4885CA2 3657/4885 |
| US-20200289486-A1 | Enantiomers Of Substituted Thiazoles As Antiviral Compounds | EIF2AK2, MAVS, ZC3HAV1 | CA12 4855/4885CA1 4850/4885CA2 4269/4885 |
| US-20250115565-A1 | SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND PROCESS OF PREPARATION THEREOF | DNA2, RECQL, BLM | CA12 3081/4885CA1 1807/4885CA2 2800/4885 |
| US-12527778-B2 | Enantiomers of a series of antiviral compounds | CA2, CA6, HCFC1 | CA12 4/4885CA1 6/4885CA2 1/4885 |
| US-20260137669-A1 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | IFNAR1, CCR10, EIF2AK2 | CA12 2877/4885CA1 4619/4885CA2 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.